Literature DB >> 8320604

Pulmonary hemodynamics after synthetic surfactant replacement in neonatal respiratory distress syndrome.

P Kääpä1, M Seppänen, P Kero, M Saraste.   

Abstract

To evaluate the acute effects of surfactant replacement therapy on pulmonary circulation in neonatal respiratory distress syndrome, we studied 25 infants before and for 1 hour after either synthetic surfactant administration (n = 15) or endotracheal suctioning (n = 10). The noninvasive Doppler method was used to estimate systolic pulmonary artery pressure from tricuspid regurgitant flow velocity and to measure blood flow velocity of the left-to-right shunt through the ductus arteriosus. Pulmonary artery pressure decreased significantly within 15 minutes after surfactant administration and remained low throughout the study period, whereas suctioning did not change pulmonary artery pressure levels. No changes in systemic pressure were found in either group. Velocity of the ductal left-to-right shunting increased and remained elevated for 1 hour only in surfactant-treated infants. In addition, right-to-left ductal shunting disappeared in four infants after surfactant administration. Our data thus indicate that administration of synthetic surfactant to infants with respiratory distress syndrome reduces pulmonary vascular resistance, resulting in a decrease in pulmonary artery pressure and an increase in ductal flow velocity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8320604     DOI: 10.1016/s0022-3476(05)81553-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  19 in total

1.  A risk-benefit assessment of natural and synthetic exogenous surfactants in the management of neonatal respiratory distress syndrome.

Authors:  H Walti; M Monset-Couchard
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

2.  Surfactant and patent ductus arteriosus.

Authors:  Abhay Kumar; Anil Lakkundi; Patrick J McNamara; Arvind Sehgal
Journal:  Indian J Pediatr       Date:  2010-01-20       Impact factor: 1.967

3.  Changes in pulmonary artery pressure in infants with respiratory distress syndrome after treatment with Exosurf.

Authors:  D Rogers
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-03       Impact factor: 5.747

4.  Indirect estimates of pulmonary artery pressure.

Authors:  P Kääpä; M Seppänen; P Kero
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1996-01       Impact factor: 5.747

Review 5.  Surfactant replacement therapy.

Authors:  M J Kresch; W H Lin; R S Thrall
Journal:  Thorax       Date:  1996-11       Impact factor: 9.139

6.  Echocardiographic assessment of patent ductus arteriosus shunt flow pattern in premature infants.

Authors:  B H Su; T Watanabe; M Shimizu; M Yanagisawa
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-07       Impact factor: 5.747

7.  The effects of surfactant on haemodynamics in hyaline membrane disease.

Authors:  J Skinner
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-03       Impact factor: 5.747

8.  Pulmonary haemodynamics after surfactant replacement in severe neonatal respiratory distress syndrome.

Authors:  M C Bloom; M Roques-Gineste; F Fries; M C Lelong-Tissier
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-09       Impact factor: 5.747

9.  Changes in pulmonary artery pressure in infants with respiratory distress syndrome following treatment with Exosurf.

Authors:  A H Hamdan; N J Shaw
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-05       Impact factor: 5.747

10.  Platelets contribute to postnatal occlusion of the ductus arteriosus.

Authors:  Katrin Echtler; Konstantin Stark; Michael Lorenz; Sandra Kerstan; Axel Walch; Luise Jennen; Martina Rudelius; Stefan Seidl; Elisabeth Kremmer; Nikla R Emambokus; Marie-Luise von Bruehl; Jon Frampton; Berend Isermann; Orsolya Genzel-Boroviczény; Christian Schreiber; Julinda Mehilli; Adnan Kastrati; Markus Schwaiger; Ramesh A Shivdasani; Steffen Massberg
Journal:  Nat Med       Date:  2009-12-06       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.